Leuthold Group LLC Acquires Shares of 7,546 United Therapeutics Corporation $UTHR

Leuthold Group LLC bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 7,546 shares of the biotechnology company’s stock, valued at approximately $3,163,000.

A number of other institutional investors and hedge funds have also made changes to their positions in UTHR. Norges Bank purchased a new stake in United Therapeutics in the 2nd quarter valued at approximately $136,453,000. Invesco Ltd. boosted its stake in shares of United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after buying an additional 419,588 shares in the last quarter. AQR Capital Management LLC grew its holdings in United Therapeutics by 40.1% during the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after acquiring an additional 364,713 shares during the period. Assetmark Inc. raised its position in United Therapeutics by 38.1% in the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after acquiring an additional 197,384 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in United Therapeutics in the second quarter valued at $55,746,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of recent analyst reports. UBS Group upped their price target on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. HC Wainwright increased their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Jefferies Financial Group reissued a “buy” rating and set a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Finally, Morgan Stanley set a $447.00 price objective on United Therapeutics in a research note on Wednesday, October 29th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $509.50.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $475.85 on Thursday. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $519.99. The business has a 50 day moving average price of $486.49 and a 200 day moving average price of $431.01. The company has a market capitalization of $20.49 billion, a P/E ratio of 18.03, a P/E/G ratio of 2.52 and a beta of 0.85.

Insider Activity at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $474.65, for a total transaction of $10,679,625.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $483.25, for a total transaction of $4,010,975.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares of the company’s stock, valued at approximately $17,774,418.25. This represents a 18.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 506,214 shares of company stock valued at $244,093,753 over the last quarter. Insiders own 10.30% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.